TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01070225
Drug: Hydrocortisone/ Placebo and Propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 400mcg Propranolol 10mg or 20 mg
Study: NCT01245569
Drug: Foster® 100/6 µg/unit dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg).
Study: NCT01245569
Drug: Seretide Accuhaler® 500/50 µg/actuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
Study: NCT01115322
Drug: Vehicle Foam without irradiation
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study: NCT01117454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, similar in appearance to flecainide
Study: NCT01117454
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.
Study: NCT01115322
Drug: Vehicle Foam with UVA and UVB irradiation
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study: NCT01115322
Drug: Vehicle Foam with UVA and UVB and visible light irradiation
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study: NCT01115322
Drug: No Treatment without irradiation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study: NCT01115322
Drug: No Treatment with UVA and UVB irradiation
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study: NCT01115322
Drug: No Treatment with UVA and UVB and visible light irradiation
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study: NCT00824733
Drug: PF03512676
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.
Study: NCT01555242
Drug: Aneustat (OMN54)
Normalized name: Laminaria angustata extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
Study: NCT00523445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
Study: NCT02264145
Drug: Ethanolic Solution From HFA134a-MDI - low
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264145
Drug: Ethanolic Solution From HFA134a-MDI - medium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264145
Drug: Ethanolic Solution From HFA134a-MDI - high
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264145
Drug: Ethanolic Solution From Respimat®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02414529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03221036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching-placebo IV infusion
Study: NCT03900325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride
Study: NCT00024271
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01855607
Drug: placebo lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
Study: NCT01736527
Drug: LE Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drop of LE Gel 0.5% administered to the study eye on visit 2
Study: NCT00483756
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
Study: NCT00483756
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
Study: NCT04329624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2.5 mg/ml injection contains riboflavine sodium phosphate 0.4 mg, dehydrated alcohol 100 mg and water for injection to 1 mL.~Immediately after skin incision patients allocated to the placebo group will receive 500 mL of 5% Glucose.
Study: NCT03538171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study: NCT00698009
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
Study: NCT04625907
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius
Study: NCT04625907
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent
Study: NCT03144115
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01495104
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses
Study: NCT03245359
Drug: Long-term ON-Q
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125%
Study: NCT01607398
Drug: ADOAIR250
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mcg inhalation, twice daily, from week0 -12.
Study: NCT01607398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation, twice daily, from week0 -12.
Study: NCT03478436
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 40 mg capsules
Study: NCT00138801
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00889616
Drug: BSAM2/Alhydrogel + CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03417401
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).
Study: NCT00326625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03901339
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally per NCCN guidelines
Study: NCT01092676
Drug: Ibuprofen Regular Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dosing
Study: NCT01092676
Drug: PRN dosing Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PRN dosing Ibupofen
Study: NCT00879762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
Study: NCT02753088
Drug: Copaxone-Teva
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02753088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01007591
Drug: LEO 80190
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied once daily
Study: NCT01007591
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Applied once daily
Study: NCT01810575
Drug: WC3036-13P/Vehicle Only 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg cream vehicle 0.5%.
Study: NCT00474370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of placebo once daily.
Study: NCT03407300
Drug: Chinese traditional medicine XH1
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
Study: NCT04083235
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil injection, USP is a colorless to faint yellow, aqueous, sterile, nonpyrogenic injectable solution available in 50 mL and 100 mL pharmacy bulk package. Each mL contains 50 mg fluorouracil in water for injection, USP.
Study: NCT02780115
Drug: AGN-199201 ophthalmic solution
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
Study: NCT02780115
Drug: AGN-190584 ophthalmic solution
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
Study: NCT02780115
Drug: AGN-199201 Vehicle
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle to AGN-199201
Study: NCT02780115
Drug: AGN-190584 Vehicle
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle to AGN-190584
Study: NCT04083235
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.
Study: NCT02296671
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02296671
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00258310
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/day for one year
Study: NCT00194116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: . Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
Study: NCT00566384
Drug: Dehydroepiandrosterone, BAY86-5314
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
Study: NCT00566384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
Study: NCT02208934
Drug: PBF-999
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5, 10, 20 and 40 mg of PBF-999
Study: NCT02208934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for all dosis of PBF-999
Study: NCT02269189
Drug: BIIL 284 BS, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02269189
Drug: BIIL 284 BS, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02269189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03741816
Drug: Indirect pulp capping
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
Study: NCT01073501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
Study: NCT03184402
Drug: DWJ1252
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03184402
Drug: Placebo of Gasmotin
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03184402
Drug: Placebo of DWJ1252
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT02814500
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT04511975
Drug: IBI188
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI188: 100 mg/mL, intravenous infusion once a week
Study: NCT03724292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo administered as oral capsule(s) once daily
Study: NCT03995251
Drug: Testosterone Supplementation
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
Study: NCT03995251
Drug: Standard Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical Treatment
Study: NCT01916291
Drug: Propess insertion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02438358
Drug: LUM015
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02549339
Drug: LEO 43204 gel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02549339
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01964755
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Study: NCT01964755
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate administered starting on Day 2, per study protocol.
Study: NCT01964755
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.
Study: NCT01209104
Drug: GSK1325756
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
Study: NCT04605991
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01268280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo in capsules administered as a single oral dose.
Study: NCT00575341
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, oral, once daily
Study: NCT04120701
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
Study: NCT00565929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline (0.9%).
Study: NCT02297438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study: NCT03851172
Drug: Ketorolac Ophthalmic
Normalized name: ketorolac ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative administration of Ketorolac 0.5% eye drops
Study: NCT03851172
Drug: Nepafenac Ophthalmic
Normalized name: nepafenac ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative administration of Nepafenac 1 mg eye drops
Study: NCT02091388
Drug: LY03004
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02091388
Drug: Risperdal® Consta®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01410565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Double Blind Phase
Study: NCT03310333
Drug: Propess® (dinoprostone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.~If the cervix is unfavourable (cervical Bishop's score \<6), the information of the study is given to the patient and the consent collected.~An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis.
Study: NCT00168766
Drug: Interferon-beta-1a (Avonex) plus methylprednisolone
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration given on 3 consecutive days, monthly as described in protocol.
Study: NCT02815722
Drug: SP2086
Approvals — FDA: no, EMA: no, PMDA: no
Description: The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
Study: NCT02815722
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
Study: NCT02922699
Drug: OMEZ 40
Normalized name: Omeza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
Study: NCT02922699
Drug: OMEZ 80
Normalized name: Omeza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
Study: NCT04093024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT00488306
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04298008
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
Study: NCT03390842
Drug: TRC101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT03390842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT02605057
Drug: LEO 80185 gel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04384692
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04384692
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03373903
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00335179
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream in 250 mg
Study: NCT04185025
Drug: Ceramides
Normalized name: GLYCOCERAMIDES
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected.